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ABSTRACT
Background. Hyperthermic intraoperative intraperitoneal
chemotherapy (HIPEC) is used to treat peritoneal surface-
spreading malignancies to maximize local drug concen-
trations while minimizing systemic effects. The
pharmacokinetic advantage of HIPEC is defined as the
intraperitoneal to intravascular ratio of drug concentrations.
We hypothesized that body surface area (BSA) would
correlate with the pharmacokinetic advantage of HIPEC.
Because oxaliplatin is administered in 5 % dextrose, we
hypothesized that BSA would correlate with glycemia.
Methods. We collected blood and peritoneal perfusate
samples from 10 patients undergoing HIPEC with a BSA-
based dose of 250 mg/m2 oxaliplatin, and measured drug
concentrations by inductively coupled plasma mass spec-
trophotometry. We monitored blood glucose for 24 h
postoperatively. Areas under concentration-time curves
(AUC) were calculated by trapezoidal rule. Pharmacoki-
netic advantage was calculated by (AUC[peritoneal fluid]/
AUC[plasma]). We used linear regression to test for sta-
tistical significance.
Results. Higher BSA was associated with lower plasma
oxaliplatin AUC (p = 0.0075) and with a greater phar-
macokinetic advantage (p = 0.0198) over the 60-minute
duration of HIPEC. No statistically significant relationships
were found between BSA and blood glucose AUC or peak
blood glucose levels.
Conclusions. Higher BSA is correlated with lower plasma
drug levels and greater pharmacokinetic advantage in
HIPEC, likely because of increased circulating blood vol-
ume with inadequate time for equilibration. Plasma glucose
levels after oxaliplatin HIPEC were not clearly related to
BSA.
The use of hyperthermic intraoperative intraperitoneal
chemotherapy (HIPEC) with oxaliplatin has been reported
for peritoneal carcinomatosis from colorectal cancer,
ovarian carcinoma, pseudomyxoma peritonei, and malig-
nant peritoneal mesothelioma.1 A goal of HIPEC is to
maximize local drug exposure to areas of tumor while
limiting systemic drug exposure; the ratio of local to sys-
temic drug concentrations is known as the pharmacokinetic
advantage.2 Because of oxaliplatin’s instability in chloride-
containing solutions, 5 % dextrose is a frequently used
carrier fluid during HIPEC.3 As in intravenous chemo-
therapy, the dose of oxaliplatin during HIPEC is usually
calculated based on body surface area (BSA).1 Some
institutions dilute the drug in a standard volume of carrier
fluid, some calculate carrier fluid volume based on BSA,
and some titrate carrier fluid volume to achieve a desired
flow rate during HIPEC.1,4,5 As a result, there is variability
between patients in the concentration of oxaliplatin in the
perfusate. Likewise, the duration of chemoperfusion has
not been standardized; perfusion times range from 30 min
to 2 h.1,6
In a previous study, the absorption of oxaliplatin during
HIPEC was associated with body mass index (BMI).4 The
goals of the current study were to test whether BSA or BMI
predict local or systemic exposure to oxaliplatin, or gly-
cemia, during and after HIPEC.
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PATIENTS AND METHODS
On an institutional review board approved protocol and
with informed consent, peritoneal fluid and blood samples
were collected during closed-technique HIPEC in ten
patients with pseudomyxoma peritonei (n = 5), malignant
peritoneal mesothelioma (n = 4), or peritoneal carcino-
matosis from colon cancer (n = 1). Patients received a
BSA-based oxaliplatin dose of 250 mg/m2 in 5 % dextrose
carrier fluid titrated to achieve a flow rate of 1 L/min over a
60-minute chemoperfusion. Samples were analyzed using
inductively coupled plasma mass spectrophotometry.
Blood glucose was analyzed for 24 h following HIPEC.
For the 60-minute duration of HIPEC (samples at 10, 30,
and 60 min) and 24-hour blood glucose levels, area under
concentration-time curve (AUC) was calculated by trape-
zoidal rule, BSA determined by DuBois and Dubois
formula, and pharmacokinetic advantage by (AUC[perito-
neal fluid]/AUC[plasma]).7 Peritoneal cancer index (PCI)
and completeness of cytoreduction (CC) scores were
determined for all patients.8,9 Linear regression was
performed using SAS 9.2.
RESULTS
Baseline characteristics of all patients, including PCI
and CC scores are listed in Table 1. One patient had a PCI
score of 0, as he had previously undergone cytoreduction
without any gross disease recurrence, and HIPEC only was
performed, without any resection.
We examined perfusate volume, BSA and BMI as
independent variables; of these, only perfusate volume and
BSA were significantly correlated. Overall pharmacoki-
netic parameters and Pearson correlation coefficients with
perfusate volume, BSA and BMI and as independent
variables are listed in Table 2. Higher perfusate volume
was associated with lower plasma oxaliplatin AUC (b =
-30.7 mg min/L2, p = 0.0170). Higher BSA was asso-
ciated with lower plasma oxaliplatin AUC (b =
-153.2 mg/m2min/L, p = 0.0075), and with a greater
pharmacokinetic advantage (b = 28.7/m2, p = 0.0198)
over the 60-minute duration of HIPEC. There were no
statistically significant relationships between perfusate
volume and peritoneal fluid oxaliplatin AUC or pharma-
cokinetic advantage, or between BSA and peritoneal fluid
oxaliplatin AUC, or between BMI and any of the phar-
macokinetic parameters. The relationships between BSA
and oxaliplatin pharmacokinetic parameters are depicted in
Fig. 1. There did not appear to be differences in pharma-
cokinetics based on diagnosis, extent of peritonectomy or
between patients with greater or lesser burdens of disease,
as measured by PCI with a cutoff of 7.
There were no statistically significant relationships
between perfusate volume, BSA or BMI, and 24-hour
glycemia or peak intraoperative blood glucose.
DISCUSSION
BSA is an imperfect but useful proxy to calculate drug
doses, because of its association with circulating blood
volume.10 Likewise, BSA has been used to estimate peri-
toneal volumes for peritoneal dialysis.11 BSA has been
shown to be a predictor of outcomes following cardiopul-
monary bypass, likely because of the association between
low BSA and hemodilutional anemia in that setting.12 We
hypothesized that the pharmacokinetics of HIPEC with
oxaliplatin would be associated with BSA, due to its known
association with circulating blood volume and peritoneal
volume.
Our results suggest that in patients who receive a BSA-
based oxaliplatin dose and carrier fluid volume titrated to
achieve a desired flow rate, BSA is a predictor of systemic
drug exposure and pharmacokinetic advantage. This is
partially explained by the inverse relationship observed
between perfusate volumes and systemic oxaliplatin levels,
as perfusate volume was found to correlate with BSA.
Patients with higher BSA had lower plasma oxaliplatin
AUC over the 60-minute duration of HIPEC, and thus
greater pharmacokinetic advantage, possibly because they
also had larger circulating blood volumes with inadequate
time for equilibration between the peritoneal and circulat-
ing blood compartments. Further studies should examine
whether these relationships hold for patients who receive a
set volume of carrier fluid, or a BSA-based volume of
carrier fluid. We did not find that BMI was a significant
predictor of pharmacokinetic parameters. The present study
differed from a previous study showing such a relationship
in terms of the patients’ diagnoses, the duration and tech-
nique of HIPEC, and surgical procedures and technique.4
We did not find obvious differences in pharmacokinetics
on the basis of diagnosis, disease burden, or extent of
peritonectomy, consistent with previous reports.13
We did not find statistically significant relationships
between BSA or BMI and glycemia in our ten patients, but
hyperglycemia was observed in all patients. Given the
relatively small amount of oxaliplatin degradation in
sodium chloride solution over the usual duration of HIPEC,
use of normal saline in the perfusion circuit (after oxa-
liplatin reconstitution in 5 % dextrose), as has previously
been described, may be considered .3,6
The present study shows that BSA can be used to predict
the pharmacokinetics of HIPEC with oxaliplatin, likely due
to the effects of circulating blood volume with inadequate
time for drug equilibration. With the exception of
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metabolic derangements due to hyperglycemia, oxaliplatin
HIPEC was well tolerated by all patients, suggesting that
the range of systemic drug levels they experienced is safe.
Patients with larger BSA, who had lower systemic drug
levels, should therefore be able to tolerate higher total
doses of oxaliplatin. This was a small cohort, however, and
we did not prospectively analyze toxicity or efficacy,
making it difficult to make clinical recommendations on
the basis of our data alone. We therefore recommend fur-
ther study of HIPEC dosing modified to achieve a desired
intraperitoneal drug concentration for all patients, rather
than a BSA-based total dose. For example, a system like
ours, which titrates carrier fluid to achieve a minimum flow
rate (which results in an variability in intraperitoneal drug
concentrations) could be modified to use oxaliplatin at a set
concentration, with the volume (and therefore the total
dose) titrated to achieve the desired flow rate (which would
result in equal intraperitoneal drug concentrations for all
patients). Patients with larger BSA would then receive a
higher total dose of drug, but, based on our data, the greater
pharmacokinetic advantage in these patients would ensure
that their systemic drug levels would remain tolerable. This
method of dosing is more consistent with the observation
that intraperitoneal oxaliplatin concentration, rather than
total dose, is the chief determinant of HIPEC pharmaco-
kinetics.14, 15
The present study does not address the most important
biodistribution endpoint, namely intratumoral drug
TABLE 1 Baseline characteristics of all patients, extent of disease and surgical treatment
ID Diagnosis Age
(years)
Sex PCI CC Extent of peritonectomy Resections Prior resections
1 Peritoneal
mesothelioma
79 M 3 0 Right diaphragm None Omentectomy
2 Pseudomyxoma
peritonei
65 F 5 0 Pelvis Omentectomy, TAH-BSO None
3 Pseudomyxoma
peritonei
57 F 4 0 Bilateral paracolic gutters Omentectomy, TAH-BSO None
4 Pseudomyxoma
peritonei
48 F 2 0 None Right hemicolectomy TAH-BSO





63 F 2 0 None Omentectomy None
7 Peritoneal
mesothelioma

















68 M 0 0 None None Omentectomy
F female, M male, PCI peritoneal cancer index score, CC completeness of cytoreduction score, TAH-BSO total abdominal hysterectomy–bilateral
salpingo-oophorectomy
TABLE 2 Pharmacokinetic parameters and Pearson correlation coefficients






Perfusate volume (L) 2.7 (0.8) – 0.788 (0.0068) 0.130 (0.7205)
BSA (m2) 1.70 (0.17) – – 0.095 (0.7935)
BMI (kg/m2) 25.8 (4.6) – – –
Plasma AUC (mg min/L) 138.1 (33.1) -0.728 (0.0170) -0.782 (0.0075) -0.054 (0.8820)
Peritoneal fluid AUC (mg min/L) 2412.9 (711.4) 0.112 (0.7590) 0.227 (0.5273) -0.402 (0.2496)
Pharmacokinetic advantage 18.6 (6.8) 0.587 (0.0744) 0.716 (0.0198) -0.334 (0.3453)
BSA body surface area, BMI body mass index, AUC area under the concentration-time curve, b estimated correlation coefficient
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concentrations, but instead uses peritoneal fluid concen-
tration as a proxy. Few tissue analysis studies have been
undertaken, and more are needed to optimize HIPEC
administration and dosing in order to achieve the highest
possible drug levels in tumor cells.16
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FIG. 1 Linear regression plots of body surface area versus oxaliplatin
pharmacokinetic parameters. BSA (m2) versus a peritoneal fluid AUC
(mg min/L) (p = 0.5273), b plasma AUC (mg min/L) (p = 0.0075),
and c pharmacokinetic advantage (p = 0.0198)
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